U.S. Drug Industry Faces Potential 200% Tariff Impact
TL;DR Summary
Merck is acquiring Verona Pharma for $10 billion to strengthen its lung-disease portfolio, while U.S. political developments threaten to impact drugmakers through potential high tariffs and Medicaid funding cuts, notably affecting companies like Gilead and Vertex. Additionally, new clinical trials are underway for gene therapies targeting muscle-wasting diseases, and Gilead has committed to providing its HIV prevention drug to millions in low-income countries at no profit.
- Which drugmakers will be hit hardest by the ‘One Big Beautiful Bill’? STAT
- Trump threatens to impose up to 200% tariff on pharmaceuticals 'very soon' CNBC
- Trump's Drug Tariffs: Where Does the U.S. Import Pharmaceuticals From? WSJ
- Trump floats 200 percent tariffs on pharmaceutical imports ‘very soon’ The Hill
- Investors shrug off Donald Trump’s 200% tariff threat on pharma Financial Times
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
5 min
vs 6 min read
Condensed
93%
1,003 → 66 words
Want the full story? Read the original article
Read on STAT